Johnson & Johnson (JNJ): Today's Featured Health Care Laggard

Editor's Note: Any reference to TheStreet Ratings and its underlying recommendation does not reflect the opinion of TheStreet, Inc. or any of its contributors including Jim Cramer or Stephanie Link.

Johnson & Johnson ( JNJ) pushed the Health Care sector lower today making it today's featured Health Care laggard. The sector as a whole closed the day up 0.8%. By the end of trading, Johnson & Johnson fell $0.88 (-1.0%) to $87.53 on light volume. Throughout the day, 6,696,342 shares of Johnson & Johnson exchanged hands as compared to its average daily volume of 9,840,000 shares. The stock ranged in price between $87.39-$88.48 after having opened the day at $88.36 as compared to the previous trading day's close of $88.41. Other companies within the Health Care sector that declined today were: Mast Therapeutics ( MSTX), down 40.6%, Rigel Pharmaceuticals ( RIGL), down 13.5%, ANI Pharmaceuticals ( ANIP), down 9.1% and Biosante Pharmaceuticals ( BPAX), down 9.1%.

Johnson & Johnson, together with its subsidiaries, engages in the research and development, manufacture, and sale of various products in the health care field worldwide. The company operates in three segments: Consumer, Pharmaceutical, and Medical Devices and Diagnostics. Johnson & Johnson has a market cap of $248.7 billion and is part of the drugs industry. Shares are up 26.1% year to date as of the close of trading on Friday. Currently there are 10 analysts that rate Johnson & Johnson a buy, no analysts rate it a sell, and 9 rate it a hold.

TheStreet Ratings rates Johnson & Johnson as a buy. The company's strengths can be seen in multiple areas, such as its revenue growth, largely solid financial position with reasonable debt levels by most measures, solid stock price performance, impressive record of earnings per share growth and compelling growth in net income. Although no company is perfect, currently we do not see any significant weaknesses which are likely to detract from the generally positive outlook.

On the positive front, Response Genetics ( RGDX), up 27.1%, Spherix ( SPEX), up 22.4%, GW Pharmaceuticals PLC ADR ( GWPH), up 18.8% and Accelerate Diagnostics ( AXDX), up 15.2% , were all gainers within the health care sector with HCA Holdings ( HCA) being today's featured health care sector leader.

For investors not wanting singular stock exposure, ETFs may be of interest. Investors who are bullish on the health care sector could consider Health Care Select Sector SPDR ( XLV) while those bearish on the health care sector could consider ProShares Ultra Short Health Care ( RXD).

STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12-months. Learn more.
null

If you liked this article you might like

Roku, Nucana and Other IPOs That Should Be on Your Radar in 2017

Crazy Weak U.S. Dollar Will Make These 10 Companies Huge Winners

Cramer: Goldman's Downgrade Of J&J Is 'Questionable'

Johnson & Johnson Stock Sinks, Goldman Downgrades to 'Sell'

The Best Companies for Women